Because amyotrophic lateral sclerosis (ALS) is such a devastating disease, there is a need for novel and efficacious therapies and several studies hypothesize that growth hormone may be one of them. In a new review paper titled “The neuroprotective effects of human growth hormone as a potential treatment for amyotrophic lateral…
A consortium dedicated to finding a cure for amyotrophic lateral sclerosis (ALS), comprised of ALS ACT, The ALS Association, ALS Finding a Cure, and the Translational Research Advancing Therapy ALS (TREAT ALS™) Northeast ALS Consortium (NEALS), has just announced the official start of acceptance of proposals for Phase II clinical trials for potentially groundbreaking treatments for the disease.
An ALS Association-sponsored meeting, held at Cold Spring Harbor Laboratory in Huntington, New York, brought together expert researchers to discuss three main themes in current amyotrophic lateral sclerosis (ALS) research: antisense therapy, gene therapy and stem cell therapy. Recent ALS therapeutic approaches have not been very successful, with only one drug,…
The Rutgers’ Human Genetics Institute of New Jersey, home to RUCDR Infinite Biologics — the world’s largest university-based biorepository — announced it has received a 5-year grant from the National Institute of Neurological Disorders and Stroke (NINDS). The $6 million funding will allow Rutgers to assume management of the NINDS stem cell repository,…
Researchers at the Dalhousie Medical School and the Brain Repair Centre in Halifax, Nova Scotia, have successfully stimulated muscle fibers directly by light, bypassing the nervous system and showing for the first time that it is possible to restore function to denervated muscles. The research study, entitled “Direct optical…
Biopharmaceutical MediciNova, Inc. will be present at the 26th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) to host a session on its therapeutic strategies for the treatment of Amyotrophic Lateral Sclerosis (ALS). The company announced it will participate in the symposium to…
Two non-profit organizations, ALS Association and Prize4Life, have joined forces to launch a new challenge grant program called The ALS Assistive Technology Challenge. Inaugurated with an initial investment of close to $500,000, the new program intends to support research projects focused on new communication technology solutions for patients who suffer from…
The finding and validation of specific disease biomarkers are an unmet medical need for amyotrophic lateral sclerosis (ALS) early diagnosis, patient care and monitoring. Neurofilaments, proteins that provide cytoskeletal support to neurons, are front and center in this scientific quest. Several studies have investigated the role of cerebrospinal fluid (CSF) neurofilaments in…
The ALS Association, a nonprofit organization of global research and support for people with ALS and the Clinical Research in ALS and related disorders for Therapeutic development (CReATe) consortium, recently announced that two new amyotrophic lateral sclerosis (ALS) research projects have been selected for funding. The studies will advance the discovery…
Cloud-based drug design and development company, Cloud Pharmaceuticals, Inc., recently announced it has partnered with THERAMetrics holding AG to collaborate on breakthrough treatments for orphan central nervous system (CNS) diseases, such as amyotrophic lateral sclerosis (ALS). ALS results in the progressive loss of structure and function of neurons, ultimately leading to their death. Symptoms depend on patients…
Get regular updates to your inbox.